Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors

Documenti analoghi

• Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach
  di: Changhui Xue, et al.
  Pubblicazione: (2025)
• Dorsomorphin Suppresses EMT to Reduce AR‐Negative Prostate Cancer Metastasis by Synergistically Antagonizing JAK2/STAT3 and Gli2‐Independent Shh Activation
  di: Dongzhang Li, et al.
  Pubblicazione: (2025)
• Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
  di: Marina Nasrin Sharifi, et al.
  Pubblicazione: (2025)
• The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
  di: Yifu Shi, et al.
  Pubblicazione: (2025)
• Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
  di: Erum Z. Whyne, et al.
  Pubblicazione: (2025)